Veru inc. (veru) shareholder alert: robbins llp reminds investors of lead plaintiff deadline in class action against veru inc.

San diego--( business wire )--the class: robbins llp reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired veru inc. (nasdaq: veru) common stock between may 11, 2022 and november 9, 2022, for violations of the securities exchange act of 1934. veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers, and also develops medicines for covid-19 and other diseases related to viral and acute respiratory distress syndrome ("ards").
VERU Ratings Summary
VERU Quant Ranking